Workflow
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities

PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Financial and corporate situation Operating deficit reduced by 24% compared to the first half of 2024, amounting to €2.7 million as of June 30, 2025Capital increase through private placements for a total amount of €6.3 million Clinical development Masitinib platform: Authorization from several European countries for the confirmatory Phase 3 study with masitinib in amyotrophic lateral sclerosi ...